NCCM
TTPH

Nine Chapters Capital Management’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Nine Chapters Capital Management’s Portfolio TTPH Stock Details TTPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-515
Closed -$95K – 222
2017
Q1 		$95K Buy
+515
New +$57.7K 0.13% 201

Other funds holding TTPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nine Chapters Capital Management's TTPH Position: Q2 2017 in Review

Nine Chapters Capital Management sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q2 2017, closing a stake of 515 shares — an estimated $95K sold.

Nine Chapters Capital Management first reported a position in TTPH in Q1 2017 and held it in 1 quarter. The position peaked at $95K in Q1 2017. 90 funds tracked by Wall St. Rank hold TTPH as of Q2 2017.

  • Nine Chapters Capital Management reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • Nine Chapters Capital Management sold 515 Tetraphase Pharmaceuticals, Inc. shares in Q2 2017, an estimated $95K.
  • Nine Chapters Capital Management first reported a position in Tetraphase Pharmaceuticals, Inc. in Q1 2017 and held it in 1 quarter.
  • Nine Chapters Capital Management's Tetraphase Pharmaceuticals, Inc. position peaked at $95K in Q1 2017.
  • 90 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q2 2017.

Based on Nine Chapters Capital Management's 13F filing for Q2 2017, filed 31 Jul 2017.